EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04139057
- Collaborators
- TCRCure Biopharma Ltd
- Investigators
- Principal Investigator: Bo Zhu, MD, PhD Army Medical University